Shanghai, China ——On April 19, 2021, VivaVision, an innovative ophthalmic drug company which invested and incubated by Viva BioInnovator, announced that it has completed a 300 million RMB D round of financing. The funds will be used to support the clinical development of a number of innovative ophthalmic drug pipelines, including the ongoing dry eye disease treatment VVN001 Phase II US clinical study.
Dr. Wang Shen, the founder and chairman of VivaVision, said, "Thanks for the continued trust and support from the investment institutions. With the joint efforts of all shareholders and management teams, VivaVision is committed to provide safer and more effective innovative therapies for global ophthalmology patients as soon as possible.
Established in August 2016, VivaVision biology is an innovative pharmaceutical company. Since its establishment, the company has focused on the research and development of international leading innovative drugs for the treatment of ophthalmic diseases, and is committed to providing better and better treatment schemes for millions of patients with ophthalmic diseases. The company has an international first-class ophthalmic team, and has established a leading product R & D pipeline. Our pipeline product vvn001 is currently in clinical stage, and other ocular surface and fundus treatment products are in different stages of development. Since its establishment, it has become one of the most leading ophthalmic innovative drug research and development companies in China.